Skip to content

Low Dose Peri-operative IV Ketamine for Chronic Post-surgery Pain Prevention

A Double-blind, Randomised Placebo-controlled Trial to Determine Whether Low-dose Intravenous Ketamine Peri-operatively Can Prevent Chronic Post-surgical Pain, in Patients Undergoing Thoracotomy or Video Assisted Thoracic Surgery (VATS)

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01296347
Enrollment
77
Registered
2011-02-15
Start date
2011-04-30
Completion date
2015-07-31
Last updated
2019-09-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Postoperative Pain

Keywords

Ketamine, Thoracotomy, VATS, Pain

Brief summary

This study will test the null hypothesis that low-dose ketamine given peri-operatively will have no effect on the development of chronic post-surgical pain, in patients undergoing thoracotomy or video assisted thoracic surgery (VATS) procedures A double-blind, randomised placebo-controlled trial will be used to test the null hypothesis. Potential participants due to undergo either thoracotomy or video assisted thoracic surgery (VATS) will be identified by the collaborating thoracic surgeons in the out-patient department. Patients will be sent information about the study by post, prior to admission for surgery. If they are willing to participate, written consent will be sought on the ward preoperatively, where they will complete baseline measures of pain. Patients will be randomised to receive an intravenous infusion of placebo (saline) or ketamine running at 0.1mg/kg/hour, starting 10 minutes prior to the surgical incision and continuing for the first three postoperative days (96 hours in total). Prior to starting the infusion a loading dose of ketamine (0.1 mg per kg) will be administered.

Detailed description

This study will test the null hypothesis that low-dose ketamine given peri-operatively will have no effect on the development of chronic post-surgical pain, in patients undergoing thoracotomy or video assisted thoracic surgery (VATS) procedures A double-blind, randomised placebo-controlled trial will be used to test the null hypothesis. Potential participants due to undergo either thoracotomy or video assisted thoracic surgery (VATS) will be identified by the collaborating thoracic surgeons in the out-patient department. Patients will be sent information about the study by post, prior to admission for surgery. If they are willing to participate, written consent will be sought on the ward preoperatively, where they will complete baseline measures of pain. Patients will be randomised to receive an intravenous infusion of placebo (saline) or ketamine running at 0.1mg/kg/hour, starting 10 minutes prior to the surgical incision and continuing for the first three postoperative days (96 hours in total). Prior to starting the infusion a loading dose of ketamine (0.1 mg per kg) will be administered. All staff, including the anaesthetist, surgical team, ward nurses and the principal investigator will be blind to the treatment given throughout the study. The key to the randomisation will be revealed at the end of the study. Patients will be asked to complete a numeric pain score (NPS) and standard pain questionnaires which includes the Brief Pain Inventory \[BPI\], short form Leeds Assessment of Neuropathic Symptoms and Signs \[S-LANSS\]) prior to surgery, then at 6 weeks, 3, 6 and 12 months after surgery. The surgical area will also be examined at 6 weeks, 6 and 12 months for signs of neuropathic or nerve pain. Whilst in hospital patients will be asked to score their pain daily, on a numeric pain scale of 0 to 10. Consumption of morphine and side-effects will be recorded. Patients will receive standard post-operative analgesia. A sample size calculation based on a previous study, to detect a reduction in pain of 2 points the 10 point numeric pain scale at the 6 week assessment, with α = 5%, 1 - β = 90% and a bilateral hypothesis, would require a sample size of 36 per group, 72 patients in total. This will require a total study population of 144 patients, as both video assisted thoracic surgery (VATS) and thoracotomy patients will be studied. A two samples t-test will be used to compare the numeric pain scores between the ketamine and placebo groups at each time point. If these data are not normally distributed then the Mann Whitney test will be used. The scores from the Brief Pain Inventory (BPI) and short form Leeds Assessment of Neuropathic Symptoms and Signs (S-LANSS) will be analysed in the same manner. The Chi Squared test will be used to compare dichotomous data, such as the incidence of side-effects.

Interventions

DRUGKetamine

Intravenous infusion of ketamine starting 10 minutes prior to surgery and running for 96 hours, which will be administered at a rate of 0.1mg/kg/hour. A loading dose of 0.1mg/kg will be administered prior to the start of the infusion

Sponsors

National Institute for Health Research, United Kingdom
CollaboratorOTHER_GOV
Imperial College Healthcare NHS Trust
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* All adult patients (18 years and above) who are undergoing either thoracotomy or video assisted thoracic surgery (VATS). * Participants must be able to understand English.

Exclusion criteria

* Patient refusal * History of previous chronic thoracic pain * Neuropathic pain (whatever the site), existing at time of recruitment * Pre-operative analgesic treatments which include the following medications: strong opioids (step 3 analgesics), tricyclic antidepressants, venlafaxine, gabapentin, pregabalin, duloxetine, clonazepam or carbamazepine. * Allergy to bupivacaine, morphine, paracetamol, tramadol, dihydrocodeine or ketamine.

Design outcomes

Primary

MeasureTime frameDescription
Pain Score on Moving at 6 Weeks6 weeks after surgeryMeasures in pain include: Numeric pain score of 0 to 10. Zero denotes 'no pain'; 10 denotes 'pain as bad as you can imagine'

Secondary

MeasureTime frameDescription
Sensory Testing6 weeks, 6 months, 12 monthsHypoaesthesia: light touch of the blunt end of a paintbrush was felt less precisely, than in healthy tissue. Hyperalgesia: the pain induced by a sterile neurotip, applied perpendicular to the skin is felt abnormally strongly, in comparison to the contralateral side. Static allodynia: the application of a Von Frey hair number 14. (8g) was unpleasant, in comparison to the contralateral side. Dynamic allodynia: three successive gentle strokes of an 8 mm-wide paintbrush over a 40 mm distance, is unpleasant, in comparison to the contralateral side.
Incidence of Side-effects, Nausea108 hoursThe presence of nausea recorded at the above time points
Analgesic Consumption (Opioid)6 weeks, 3 month, 6 monthAnalgesia consumption will be measured post-operatively and at 6 weeks
Incidence of Side Effect, Lightheaded108 hoursThe presence of lightheaded recorded at the above time points
Incidence of Side Effect, Vivid Dreams108 hoursThe presence of vivid dreams recorded at the above time points
Incidence of Side Effect, Vomiting108 hoursThe presence of vomiting recorded at the above time points

Countries

United Kingdom

Participant flow

Participants by arm

ArmCount
Saline
Patients will receive a placebo infusion of 0.9% sodium chloride, which will start 10 minutes prior to the start of the operation and continue for 96 hours.
35
Ketamine
Patients will receive intravenous ketamine, starting 10 minutes prior to surgery and will continue for 96 hours Ketamine: Intravenous infusion of ketamine starting 10 minutes prior to surgery and running for 96 hours, which will be administered at a rate of 0.1mg/kg/hour. A loading dose of 0.1mg/kg will be administered prior to the start of the infusion
35
Total70

Withdrawals & dropouts

PeriodReasonFG000FG001
12 Month Follow upDeath11
12 Month Follow upLost to Follow-up31
12 Month Follow upWithdrawal by Subject01
3 Month Follow upDeath10
3 Month Follow upLost to Follow-up01
6 Month Follow upDeath21
6 Month Follow upLost to Follow-up01
6 Week Follow upDeath01
AllocationLack of Efficacy12
Allocationnot received infusion10
AllocationWithdrawal by Subject12

Baseline characteristics

CharacteristicSalineKetamineTotal
Age, Continuous68 years61 years64.5 years
Region of Enrollment
United Kingdom
35 participants35 participants70 participants
Sex: Female, Male
Female
23 Participants15 Participants38 Participants
Sex: Female, Male
Male
12 Participants20 Participants32 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 380 / 39
other
Total, other adverse events
34 / 3839 / 39
serious
Total, serious adverse events
8 / 389 / 39

Outcome results

Primary

Pain Score on Moving at 6 Weeks

Measures in pain include: Numeric pain score of 0 to 10. Zero denotes 'no pain'; 10 denotes 'pain as bad as you can imagine'

Time frame: 6 weeks after surgery

Population: Ketamine group one participant did not have data

ArmMeasureValue (MEDIAN)
SalinePain Score on Moving at 6 Weeks0 units on a scale
KetaminePain Score on Moving at 6 Weeks1.5 units on a scale
p-value: 0.33Wilcoxon (Mann-Whitney)
Secondary

Analgesic Consumption (Opioid)

Analgesia consumption will be measured post-operatively and at 6 weeks

Time frame: 6 weeks, 3 month, 6 month

Population: Participant who experienced pain.

ArmMeasureGroupValue (MEDIAN)
SalineAnalgesic Consumption (Opioid)6 weeks9 mg
SalineAnalgesic Consumption (Opioid)3 months21 mg
SalineAnalgesic Consumption (Opioid)6 months34 mg
KetamineAnalgesic Consumption (Opioid)6 weeks0 mg
KetamineAnalgesic Consumption (Opioid)3 months17 mg
KetamineAnalgesic Consumption (Opioid)6 months9 mg
Comparison: 6 weeksp-value: 0.71Wilcoxon (Mann-Whitney)
Comparison: 3 monthp-value: 1Wilcoxon (Mann-Whitney)
Comparison: 6 monthsp-value: 0.32Wilcoxon (Mann-Whitney)
Secondary

Incidence of Side Effect, Lightheaded

The presence of lightheaded recorded at the above time points

Time frame: 108 hours

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
SalineIncidence of Side Effect, Lightheaded5 Participants
KetamineIncidence of Side Effect, Lightheaded14 Participants
p-value: 0.02Wilcoxon (Mann-Whitney)
Secondary

Incidence of Side-effects, Nausea

The presence of nausea recorded at the above time points

Time frame: 108 hours

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
SalineIncidence of Side-effects, Nausea14 Participants
KetamineIncidence of Side-effects, Nausea17 Participants
p-value: 0.47Wilcoxon (Mann-Whitney)
Secondary

Incidence of Side Effect, Vivid Dreams

The presence of vivid dreams recorded at the above time points

Time frame: 108 hours

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
SalineIncidence of Side Effect, Vivid Dreams2 Participants
KetamineIncidence of Side Effect, Vivid Dreams13 Participants
p-value: 0.001Wilcoxon (Mann-Whitney)
Secondary

Incidence of Side Effect, Vomiting

The presence of vomiting recorded at the above time points

Time frame: 108 hours

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
SalineIncidence of Side Effect, Vomiting8 Participants
KetamineIncidence of Side Effect, Vomiting8 Participants
p-value: 1Wilcoxon (Mann-Whitney)
Secondary

Sensory Testing

Hypoaesthesia: light touch of the blunt end of a paintbrush was felt less precisely, than in healthy tissue. Hyperalgesia: the pain induced by a sterile neurotip, applied perpendicular to the skin is felt abnormally strongly, in comparison to the contralateral side. Static allodynia: the application of a Von Frey hair number 14. (8g) was unpleasant, in comparison to the contralateral side. Dynamic allodynia: three successive gentle strokes of an 8 mm-wide paintbrush over a 40 mm distance, is unpleasant, in comparison to the contralateral side.

Time frame: 6 weeks, 6 months, 12 months

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026